Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis in Patients on Palliative Treatment for Advanced Breast Cancer

The study conducted in Germany with 104 postmenopausal patients with advanced breast cancer (aBC) found that quality of life (QoL), particularly "physical agility and mobility," was the most important factor in treatment decisions, followed by overall survival (OS) and progression-free survival (PFS). Side effects were less critical unless they severely impacted QoL, with nausea/vomiting being the most significant. Hair loss was notably more important to first-line patients. The study concluded that QoL, OS, and PFS should be equally considered in treatment decisions, as patients were willing to accept moderate side effects if QoL was maintained and OS/PFS were improved. Previous treatment experiences had little influence on current decisions.